• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Notice of Annual General Meeting October 2025

by chantal | Oct 3, 2025 | Annual General Meeting

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Director Dealing

by chantal | Sep 16, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Presentation of Year End Results: 11 September 2025

by chantal | Sep 12, 2025 | Investor Presentations

Scancell CEO on 2025 Milestones and Road ahead

by chantal | Sep 12, 2025 | Investor Presentations

Scancell Financial Year End 2025 Results

by chantal | Sep 11, 2025 | Investor Presentations, Investors, Presentations

« Older Entries
Next Entries »

Recent Posts

  • Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma
  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy